Tianchen Bio-B (01779): Proposal to adopt H-share share option plan and H-share share incentive plan

Tianchen Bio-B (01779) announced that on July 15, 2026, the Board of Directors resolved to recommend the adoption of the Company's H-share share option plan and H-share share incentive plan.

Zhitong FinanceJul 16 06:49

Tianchen Bio-B (01779.HK): Proposal to adopt H-share share option plan and H-share share incentive plan

Gelonghui, July 16 — Tianchen Bio-B (01779.HK) announced that on July 15, 2026, the board of directors resolved to recommend the adoption of the company's H-share share option plan and H-share share incentive plan.

Gelonghui FinanceJul 16 06:47

HK Market Movers | Tensent Bio-B (01779) Rises Over 7% as U.S. FDA Approves Clinical Trial Application for LP-003 in Peanut Allergy Indication

Tianchen Bio-B (01779) rose more than 7%. As of the time of writing, it was up 7.77% at HK$89.45, with a trading volume of HK$3.1726 million.

Zhitong FinanceJul 15 15:12

Tianchen Bio-B (01779): FDA Approves IND Application for LP-003 for Peanut Allergy Indication

Tianchen Bio-B (01779) announced that the Investigational New Drug (IND) application for LP-003, targeting peanut allergy, has been approved by the U.S. Food and Drug Administration (FDA).

Zhitong FinanceJul 13 08:16

Tianchen Bio-B (01779) reported a total custodied market value of HK$927 million, with company shareholders depositing 10.3378 million shares into Guojin Securities Hong Kong.

On July 10, Tianchen Bio-B (01779) experienced unusual position activity, with a total stored position market value of HK$927 million, accounting for 13.74%.

Zhitong FinanceJul 13 08:11

Tianchen Bio-B (01779) issued 2,128,950 shares due to the full exercise of the over-allotment option.

Tianchen Bio-B (01779) announced the issuance and allocation of 2.12895 million H-shares on July 6, 2026, upon full exercise of the over-allotment option.

Zhitong FinanceJul 6 19:18